Cargando…

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

BACKGROUND: Bone complications (pathologic fracture, spinal cord compression, surgery to bone and radiation to bone) are a common problem in patients with multiple myeloma (MM). We set out to provide insights into the real-world burden of bone complications in patients with newly diagnosed MM (NDMM)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mateos, María-Victoria, Fink, Leah, Koneswaran, Niranchana, Intorcia, Michele, Giannopoulou, Christina, Niepel, Daniela, Cavo, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055060/ https://www.ncbi.nlm.nih.gov/pubmed/32126974 http://dx.doi.org/10.1186/s12885-020-6596-y

Ejemplares similares

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review
por: Mohty, Mohamad, et al.
Publicado: (2019)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
por: Maher, Toby M., et al.
Publicado: (2017)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019)

Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States
por: Qian, Yi, et al.
Publicado: (2017)

Patient perspective on the management of atrial fibrillation in five European countries
por: Bakhai, Ameet, et al.
Publicado: (2013)

Needs of forensic psychiatric patients with schizophrenia in five European countries
por: Oberndorfer, R., et al.
Publicado: (2022)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
por: Musto, Pellegrino, et al.
Publicado: (2021)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
por: Facon, Thierry, et al.
Publicado: (2022)

P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
por: Facon, Thierry, et al.
Publicado: (2022)

P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
por: Beksac, Meral, et al.
Publicado: (2023)

Patient preferences for characteristics of antiretroviral therapies: results from five European countries
por: Gazzard, Brian, et al.
Publicado: (2014)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
por: Caers, Jo, et al.
Publicado: (2018)

Cap dependent translation contributes to resistance of myeloma cells to bortezomib
por: Mancino, Marilena, et al.
Publicado: (2013)

The Impact of Chronic Urticaria from the Patient’s Perspective: A Survey in Five European Countries
por: Balp, Maria-Magdalena, et al.
Publicado: (2015)

Trends of Phase I Clinical Trials in the Latest Ten Years across Five European Countries
por: Di Tonno, Davide, et al.
Publicado: (2022)

Charting the European Course to the High-Energy Frontier
por: Aslanides, E., et al.
Publicado: (2019)

Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma
por: Batra, Anu, et al.
Publicado: (2014)

Management of cardiovascular risk in patients with multiple myeloma
por: Plummer, Chris, et al.
Publicado: (2019)

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
por: Goldschmidt, Hartmut, et al.
Publicado: (2020)

Use of National and International Growth Charts for Studying Height in European Children: Development of Up-To-Date European Height-For-Age Charts
por: Bonthuis, Marjolein, et al.
Publicado: (2012)

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
por: Hungria, Vania, et al.
Publicado: (2020)

Burden of chronic urticaria relative to psoriasis in five European countries
por: Balp, M.M., et al.
Publicado: (2017)

Change Management and Digital Innovations in Hospitals of Five European Countries
por: Hospodková, Petra, et al.
Publicado: (2021)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Use of psychiatric hospitals and social integration of patients with psychiatric disorders: a prospective cohort study in five European countries
por: Smith, Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8p8m9fgh4662e53h4260iji5ho